Davide Capodanno @DFCapodanno · 23 Aug 2026
The 10 trials I am most looking forward to at the ESC Hot Lines next week (in no particular order): LIBREXIA-ACS, where milvexian could end up like apixaban in APPRAISE-2, perhaps with less bleeding. Rivaroxaban did not exactly have an easy story after ATLAS ACS 2 either, https://t.co/FqC2LZh8H3
15 733Views
197Likes
62Reposts
6Replies
4Quotes
109Bookmarks
Is that a lot?
10.3×vs this author's median1 521 views is typical
73Percentile for this authorof 11 recent posts
7.70×vs 10K–100K median2 043 views is typical
68.57%Reachviews ÷ followers
1.71%Engagement rateof viewers reacted